Hevylite® reimbursement in South Korea
Congratulations to DOW Biomedica, our distributor in South Korea, who have Hevylite reimbursement approval from their Health Insurance Review Agency. The official process started in 2013, and was completed on July 1st 2016.
In South Korea, it is the clinicians who apply for reimbursement so the challenge for DOW Biomedica was to educate and convince the haematologists of the value of Hevylite. This was achieved through local papers showing its benefit compared to current techniques, plus numerous seminars and meetings over many months. The reimbursement was endorsed by the Korean Multiple Myeloma Working Party.
There is no limitation on Hevylite utility so DOW Biomedica will focus on:
• Confirmation/baseline at diagnosis
• Prognosis
• Monitoring alongside Freelite
• Special highlight on the use of “normalization of Hevylite and Freelite as a gatekeeper for further investigation of minimal residual disease”
YG Shin, President and CEO of DOW Biomedica said, “We recognize the huge amount of scientific support and marketing guidance provided from the headquarters of Binding Site, which was essential for our work. We are very much pleased to share the pleasure with those colleagues altogether. Reimbursement is a road itself for clinicians to drive on, and we need to work further for making it a highway.”
Hevylite is a serum test that is used to monitor multiple myeloma. Learn more here.